Broad applications in cell based assays, ranging from cell therapy and regenerative medicine to drug discovery and diagnostics.

Drug Discovery


Drug Discovery /
Functional Genomics

Pooled high content phenotypic screens of genes and drugs compatible with multiple libraries including CRISPR gRNAs, shRNAs, antibodies, and even small compounds.

Pooled High-Content Screening of
Genes and Drugs

Our Solution for Cell Therapy

Image-based high-content screening (HCS) is a powerful method for identifying genes and compounds that induce physiologically relevant disease-linked cellular phenotypes. However, it is time-consuming and expensive owing to its reliance on well-to-well imaging of microplates. In contrast, a pooled screen offers a high throughput and cost effective method involving conventional flow cytometry. However, the readouts are limited to fluorescence and light scattering from known biomarkers.
Using ThinkCyte’s proprietary machine Vision-based Cell Sorting (ViCS) technology, we have developed a new method that enables high-throughput image-based HCS in a pooled format. This novel method is compatible with various types of libraries, including CRISPR gRNAs, shRNAs, antibodies, peptides, and small compounds.

From array to pool

Key Advantages of Our Technology

  • Applicable to
    a variety of libraries
    Usable to your own compound, CRISPR, shRNA, peptide, phage libraries, etc.
  • High speed sorting
    • Pathway-specific libraries: 1–3 h
    • Whole-genome libraries: 8–12 h
    • Compound libraries (~100,000 compounds): 1–3 d
  • For precious cells
    Only a few hundred cells per gene/compound are required for screening
  • Link genotypes to phenotypes
    Image data is linked to the NGS data
  • Economical
    Reduce reagents, labor, and analysis time

Phenotype-driven Target Validation in Drug Discovery

In the phenotypic screening process, identification of disease relevant phenotypes is crucial. Our screening platform is able to detect various types of phenotypes, such as changes in protein localization, aggregation, and cell and organelle morphology, using fluorescence reporters. Furthermore, our proprietary machine vision-based classification technique can discriminate morphological differences of cells including live and apoptotic cells, differentiated and undifferentiated cells, and healthy and disease relevant cells, without the use of molecular labels. These label-free phenotypes can be also used in our screening system.

Disease-relevant phenotypes of cells
  • Phenotype
    of Interest
    • Nuclear
      Nuclear Translocation
    • PPI,
      PPI, Aggregation
    • Organelle
      Organelle Morphology
  • Imaging
    • LPS(+) LPS(+)
      LPS(-) LPS(-)
    • Untreated Untreated
      Nutlin-3 Nutlin-3
    • Mitochondria Mitochondria
      Lysosome Lysosome
    • Apoptotic Status
    • Differentiation
    • Disease vs Healthy
  • Imaging
    • Live Live
      Apoptotic Apoptotic
    • Differentiated Differentiated
      Undifferentiated Undifferentiated
    • Cancerous Cancerous
      Healthy Healthy

Screening Workflows

Our screening platform enables image-based high-content screens in a pooled format that can dramatically accelerate the screening process while reducing costs. It is compatible with a wide range of libraries, including CRISPR gRNAs, shRNAs, antibodies, peptides, and small compounds.

Pooled screening of genes

Our technology is applicable for screening of genes using lentivirus libraries including CRISPR library.

Pooled screening of genes
Pooled screening of drugs

Combining our proprietary ViCS technology with DNA barcoding and droplet techniques, image-based high-content screens can be performed for small molecule libraries in a pooled format as well.

Pooled screening of drugs


Interested in our technology?
Contact us to be part of our early access program.